Biofrontera Inc. to Participate in Benchmark’s 11th Annual Discovery One-on-One Investor Conference
30 Novembre 2022 - 8:08PM
Biofrontera
Inc. (Nasdaq: BFRI),
a biopharmaceutical company specializing in the commercialization
of dermatological products, announced today that the Company will
be participating in Benchmark’s 11th Annual Discovery One-on-One
Investor Conference being held on December 1, 2022 in New York, NY.
Erica Monaco, Chief Executive Officer, and
Hermann Lübbert, Executive Chairman of Biofrontera Inc. will be
meeting with registered investors in one-on-one meetings and
small-group sessions.
About Biofrontera Inc.
Biofrontera Inc. is a U.S.-based
biopharmaceutical company commercializing a portfolio of
pharmaceutical products for the treatment of dermatological
conditions with a focus on PDT and topical antibiotics. The
Company’s licensed products are used for the treatment of actinic
keratoses, which are pre-cancerous skin lesions, as well as
impetigo, a bacterial skin infection. For more information, visit
https://www.biofrontera-us.com.
Contacts
Biofrontera Inc.Anke zur
Mühlen+1 781 486 1539us-ir@biofrontera.com
LHA Investor RelationsTirth T.
Patel+1 212 201 6614tpatel@lhai.com
# # #
Grafico Azioni Biofrontera (NASDAQ:BFRIW)
Storico
Da Gen 2025 a Feb 2025
Grafico Azioni Biofrontera (NASDAQ:BFRIW)
Storico
Da Feb 2024 a Feb 2025
